First Tracks Biotherapeutics Net Debt/FCF

What does First Tracks Biotherapeutics do? First Tracks Biotherapeutics develops immunology therapeutics for autoimmune and inflammatory diseases in the United States. Its products include ANB033, a novel anti-CD122 antagonist targeting the shared beta subunit of IL-15 and IL-2 receptors; Rosnilimab, an antibody engineered to selectively deplete pathogenic T cells in peripheral and inflamed tissues; and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. The company was formerly Biopharma Co., Inc., renaming to First Tracks Biotherapeutics in February 2026 after founding in 2019. It operates in the clinical-stage biotechnology sector with a focus on autoimmune and inflammatory disease treatments. The company generates revenue through the development and potential commercialization of its pipeline products. ANB033, Rosnilimab, and ANB101 represent its core therapeutic candidates targeting specific immune pathways. These products are developed for clinical trials and eventual market entry, with potential licensing agreements or partnerships for further development and distribution. The target segments include patients with autoimmune and inflammatory conditions seeking novel treatment options. First Tracks Biotherapeutics focuses on delivering innovative therapeutics for unmet medical needs in immunology. Its product portfolio targets key immune mechanisms involved in autoimmune and inflammatory diseases, aiming to provide more effective and targeted treatments. The company's development strategy centers on advancing its clinical-stage candidates toward regulatory approval and market availability. First Tracks Biotherapeutics is one of the most popular companies on Eulerpool.